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Identification of novel DNA-damage tolerance
genes reveals regulation of translesion DNA
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Cells cope with replication-blocking lesions via translesion DNA synthesis (TLS). TLS
is carried out by low-fidelity DNA polymerases that replicate across lesions, thereby pre-
venting genome instability at the cost of increased point mutations. Here we perform a two-
stage siRNA-based functional screen for mammalian TLS genes and identify 17 validated TLS
genes. One of the genes, NPM1, is frequently mutated in acute myeloid leukaemia (AML). We
show that NPM1 (nucleophosmin) regulates TLS via interaction with the catalytic core of
DNA polymerase-Z (polZ), and that NPM1 deficiency causes a TLS defect due to protea-
somal degradation of polZ. Moreover, the prevalent NPM1cþ mutation that causes NPM1
mislocalization in B30% of AML patients results in excessive degradation of polZ. These
results establish the role of NPM1 as a key TLS regulator, and suggest a mechanism for the
better prognosis of AML patients carrying mutations in NPM1.
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T
he high abundance of DNA damage has led to the
evolution of a variety of DNA-damage tolerance and repair
pathways that minimize potential deleterious effects on
DNA replication and gene expression, thereby preventing genome
instability and a plethora of pathological conditions1. Most of the
damage is repaired by accurate DNA repair mechanisms, primarily
during the G1 phase of the cell cycle. However, during S phase,
DNA replication encounters DNA lesions that have escaped repair,
or that were newly formed, leading to the arrest of replication forks
and/or the formation of single-stranded gaps, which may further
lead to the formation of double-stranded breaks (DSB) and genome
instability2. These replication obstacles are dealt with by DNA-
damage tolerance3, of which two main strategies are known: (1)
translesion DNA synthesis (TLS), whereby specialized low-fidelity
DNA polymerases replicate across the damaged DNA region in a
process that is inherently error prone4–7; and (2) homology-
dependent repair in which the gap opposite the DNA lesion is
filled-in by either physical transfer of the complementary strand
from the sister chromatid or by using the latter as a template for
copying the missing strand (also termed error-free post-replication
repair or template switch repair)8–13. The importance of TLS is
highlighted by the hereditary disease xeroderma pigmentosum
variant (XPV), which is characterized by sunlight sensitivity and
very high predisposition to skin cancer, caused by germline
mutations that inactivate DNA polymerase-Z (polZ), a major TLS
DNA polymerase14,15. The realization that TLS maintains a low
mutagenic burden despite its inherent error-prone nature, and
protects cells against genome instability and cancer, raised great
interest in this process5,6. TLS usually involves two DNA
polymerases: an inserter, which incorporates a nucleotide
opposite the damaged template base, and an extender, which
continues DNA synthesis beyond the damaged base16,17. Several
layers of TLS regulation are known, including damaged-induced
monoubiquitination of proliferating cell nuclear antigen (PCNA),
the sliding DNA clamp, which serves to recruit TLS DNA
polymerases to damaged sites in the DNA18–24 and clearance of
TLS polymerases from the DNA by the activity of DVC1 and p97
(refs 21,22). In terms of cell physiology, TLS largely operates
uncoupled from DNA replication, during late S and early G2
phases of the cell cycle25–27, and is also regulated by the DNA-
damage response via the ataxia telangiectasia and Rad3-related
(ATR) protein28,29 and via p53/p21 (refs 30–32). The high
complexity of TLS in mammalian cells and its involvement in
the development of cancer drug resistance33–37 highlights the
importance of understanding how this process is regulated. While
previous studies aimed to systematically identify TLS genes in
Saccharomyces cerevisiae proved to be highly useful in the field, to
the best of our knowledge, screening for mammalian TLS genes has
not been yet reported, and high-throughput assays for mammalian
TLS are currently not available.
Here we present the development of a high-throughput assay
for TLS in mammalian cells, and its implementation in screening
1,000 candidate genes. We further describe the validation of 17
novel TLS players, and the mechanistic and clinical insights
revealed by investigating one of them, nucleophosmin, encoded
by the NPM1 gene. We show that NPM1 regulates TLS by
protecting polZ from proteasomal degradation, and that a
deficiency in NPM1 as well as expression of the acute myeloid
leukaemia (AML)-related NPM1cþ mutation results in
decreased polZ levels and defective TLS. Our results uncover
multiple novel TLS regulators in mammalian cells and implicate
NPM1 in the proteolytic regulation of TLS polymerases.
Results
Two-stage functional siRNA screen for mammalian TLS genes.
We performed a two-stage functional short interfering RNA
(siRNA) screen designed to identify new mammalian TLS genes.
In the first stage, we assayed ultraviolet sensitivity using an XPA
cell line that is deficient in nucleotide excision repair (NER), and
therefore defective in the repair of ultraviolet-induced DNA
damage. Consequently, ultraviolet survival of the XPA cells
exhibits a greater dependence on DNA-damage tolerance com-
pared with NER-proficient cells38, making the screen more
selective to DNA-damage tolerance genes. siRNAs that were
identified in this stage as significantly affecting ultraviolet survival
were re-screened with a second more stringent assay, which
measured TLS. This strategy was used to screen 1,000 siRNAs
directed to genes involved in DNA repair, ubiquitination and de-
ubiquitination, cell cycle regulation and cancer. The ultraviolet-
sensitivity screen (Fig. 1a) was performed in three biological
replicas, exhibiting good reproducibility (Fig. 1b). Of the 1,000
genes assayed, we found 192 genes for which knockdown resulted
in elevated ultraviolet sensitivity, and 45 genes that reduced
ultraviolet sensitivity (false discovery rate (FDR) o8%; Fig. 1c,
Supplementary Data 1, Supplementary Table 1 and
Supplementary Fig. 1). Known TLS genes, as well as genes
related to the ATR DNA-damage response pathway, but not
other DNA repair pathways, were highly represented among the
hits (Fig. 1d), suggesting that the XPA deficiency indeed enriched
for genes involved in TLS.
The second screening stage was performed using a newly
developed high-throughput TLS assay. It is a modification of an
assay based on plasmids containing a site-specific DNA lesion
opposite a gap, previously successfully used to study TLS17,32,38.
In the new assay, the gap lesion is positioned between a
cytomegalovirus (CMV) promoter and a firefly luciferase (Fluc)
reporter gene (Fig. 2a). The presence of a gap in the transcribed
strand does not allow expression of the Fluc gene, unless the
missing segment of the coding strand is synthesized by TLS. A
lesion-free gapped plasmid expressing Renilla luciferase (Rluc)
served to normalize for transfection and gap-filling efficiencies
(Fig. 2b). Of note, the product of a successful TLS event in the
Fluc system still carries the lesion on the non-transcribed strand,
which might interfere with Fluc expression. To test this
possibility, we constructed the expected TLS product, namely a
fully double-stranded plasmid with the lesion on the non-
transcribed strand, and found that its Fluc expression in XPA cells
was essentially identical to that obtained with a control plasmid
without the lesion (Supplementary Fig. 2a).
The high-throughput TLS system was utilized to screen 237
siRNA hits from the primary screen for involvement in TLS
across each of two major ultraviolet irradiation-induced DNA
lesions, namely thymine–thymine 6-4 photoproduct (TT 6-4 PP)
and thymine–thymine cyclobutane pyrimidine dimer (TT CPD;
Fig. 2c–e). Screening was performed in four independent
biological replicas performed on different days and exhibited
high reproducibility (Fig. 2f,g). To normalize for differential
damage-independent knockdown effects on Fluc and Rluc
expression, each siRNA was also tested using Fluc and Rluc
plasmids both carrying gaps but no lesions (NLs), and the results
served to correct the data (Supplementary Fig. 2b,c). TLS
elevation or inhibition scores were calculated with respect to
control siRNAs, and were subjected to statistical analysis
(Supplementary Fig. 2d–f). This screen resulted in 47 novel hits
and 12 known TLS genes (FDR o10%; Supplementary Data 1
and Supplementary Table 1). Importantly, known TLS genes, but
not other DNA repair pathways, were further enriched among the
hits (Fig. 2h and Supplementary Table 2), indicating high
specificity of the screening method towards the TLS pathway.
The ATR signalling pathway was also enriched to some extent, in
agreement with recent reports28,29. Repetitive examination of
each hit using four different siRNA oligos, to minimize off-target
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effects, excluded 30 of the genes, yielding 17 validated novel TLS
genes (Table 1).
Functional validation of candidate TLS genes. To further vali-
date the hits, a second version of the TLS assay was developed
based on quantitative PCR (qPCR) readouts rather than gene
expression (Fig. 3a). In brief, following TLS in mammalian cells,
the plasmids were extracted under alkaline conditions, which
denatured gapped plasmids but not the covalently closed pro-
ducts of TLS or the control gap-filling reactions. Remnants of
gapped plasmids were digested with S1 single-stranded endonu-
clease. TLS efficiency was calculated as the ratio between the
products of qPCRs that targeted the filled-in gap-lesion plasmid
and the filled-in control gapped plasmid, and was normalized to
control siRNA-treated samples (Fig. 3a). The qPCR-based TLS
assay was utilized to examine the involvement of 10 selected hits
in TLS across the TT 6-4 PP ultraviolet lesion in mouse
embryonic fibroblasts (MEFs). In parallel, TLS was measured
across the major tobacco smoke-induced DNA adduct ben-
zo[a]pyrene-guanine (BP-G), a non-ultraviolet lesion. Six hits,
namely Papd7, Ruvbl2, Trip11, Npm1, Abh2 and Ube2e1, sig-
nificantly affected TLS across both DNA lesions, although the
effects obtained for Abh2 and Ube2e1 were rather small (Fig. 3b,
t-test, P values o0.05; knockdown efficiencies are shown in
Fig. 3c). Cyld, Mcm3, Dclre1a and Ercc4 affected TLS across TT 6-
4 PP but not across BP-G (Fig. 3b, Cyld knockdown reduced TLS
across BP-G, but gave a marginal P value of 0.06). Of notice, all
the 10 tested human genes were validated in the qPCR-based TLS
assay with at least one DNA lesion in MEFs. Four genes were
further tested for their impact on TLS extent and mutagenicity in
a gapped plasmid assay in which the readout is based on trans-
formation of Escherichia coli cells, and therefore enables deter-
mining the sequence signature of TLS events17,32,38. Knocking
down the expression of each of the tested genes, namely Cyld,
Npm1, Papd7 and Ruvbl2, significantly reduced TLS efficiency
across the BP-G adduct (Fig. 3d; two-tailed t-test, P values
o0.02). DNA sequence analysis showed that in control cells TLS
was 47% accurate (insertion of a dCMP opposite BP-G), and 53%
were point mutations, most of which (87%) were caused by
insertion of dAMP opposite the lesion (Fig. 3e), consistent with
previous results17,39. Interestingly, knocking down the expression
of each of the four tested genes also caused, in addition to the
decrease in the extent of TLS, a lower error rate among the TLS
events (Fig. 3e).
NPM1 regulates DNA polg promoted TLS. Among the novel
TLS genes, we concentrated for further analysis on NPM1,
a gene frequently mutated in AML40. NPM1 (also termed
nucleophosmin or B23) is a multi-functional protein involved in
diverse cellular processes such as ribosome biogenesis, histone
assembly, protein chaperoning and cell proliferation41. To
explore the possibility that NPM1 affects polZ-promoted TLS,
we tested TLS across three lesions that are bypassed by polZ: the
sunlight-induced TT CPD and two adducts formed by the
chemotherapy drug cisplatin, namely cisPt-GG and cisPt-GTG.
As can be seen in Fig. 4a, in MEF cells in which Npm1 was
knocked down, TLS across each of the three lesions was
significantly reduced (two-tailed t-test, P values o0.02), with
the TT CPD being most affected. In contrast, knocking down
Npm1 in polZ-deficient PolH / MEF cells did not significantly
affect TLS across the TT CPD lesion (Supplementary Fig. 3a,b),
further suggesting that the effect of NPM1 on TLS across TT CPD
is mediated via polZ. This effect was not indirectly mediated via
APE1, the base excision repair endonuclease that is regulated by
NPM1, since knocking down the expression of Ape1 in the MEF
cells had no effect on TLS across TT CPD (Supplementary
Fig. 3c,d). Since NPM1 was reported to control the levels of
PCNA42, we examined whether the effect on TLS is via reducing
PCNA monoubiquitination, which is needed for effective
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Figure 1 | Primary screen for ultraviolet sensitivity in NER-deficient human cells. (a) An outline of the primary screen. In brief, NER-deficient XPA cells
were transfected with the siRNA libraries on day 0, exposed to ultraviolet C (UVC) irradiation (1 J m 2) on day 2 and analysed for cell viability on day 4.
(b) Data reproducibility. Luminescence values of three biological replicas that were preformed on different days were plotted against each other. (c)
Histogram describing ultraviolet-sensitivity fold change (FC) caused by the siRNAs (median values over the three replicas). Dashed red lines denote the
distribution borders of negative control samples. (d) Enrichment of TLS, DNA repair and DNA-damage response pathways within the screen hits. Dashed
red line corresponds to a hypergeometric test P value 0.05. NER, nucleotide excision repair; BER, base excision repair; MMR, mismatch repair; FA, the
Fanconi anemia pathway; NHEJ, non-homologous end joining; HRR, homologous recombination repair; ATM and ATR, the two main DNA-damage response
pathways. See also Supplementary Fig. 1, Supplementary Data 1 and Supplementary Table 1.
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effective TLS23. Interestingly knocking down the expression of
NPM1 increased PCNA monoubiquitination rather than
decreasing it (Supplementary Fig. 4). This rules out the
possibility that the TLS deficiency is owing to a PCNA-
ubiquitination defect. A possible explanation for this
observation is that the TLS defect caused by knockdown of
NPM1 increases the number of stalled replication forks that leads
to increased PCNA monoubiquitination.
NPM1 interacts with DNA polg in the nucleus. We next
examined the interaction between polZ and NPM1 by co-
immunoprecipitation (co-IP) of the endogenous NPM1 with
endogenous polZ. As can be seen in Fig. 4b, immunoprecipitation
(IP) of polZ with a specific antibody caused co-precipitation of
NPM1. No NPM1 was observed when a control IgG was used
(Fig. 4b, lane 2). To probe the subcellular compartment in which
NPM1 and polZ interact, we resorted to the proximity ligation
assay (PLA). As can be seen in Fig. 4c, interaction foci between
polZ and NPM1 were clearly observed in human MRC5sv cells
and localized mainly in the nucleus (the green spots in Fig. 4c
upper panel, and quantified in Fig. 4d). These interaction foci
were not observed in control XPV cells that lack polZ (Fig. 4c
middle panel, and Fig. 4d), but appeared in XPV cells com-
plemented with the POLH gene, encoding polZ (Fig. 4c lower
panel, and Fig. 4d). The interaction foci appear to be distributed
throughout the nucleus but were excluded from the nucleoli
(Supplementary Fig. 5a). Similarly, in MRC5sv cells co-expressing
green fluorescent protein (GFP)-tagged polZ and mCherry-tag-
ged NPM1, GFP-polZ was distributed throughout the nucleus
and in reduced amounts in the nucleoli (Supplementary Fig. 5b).
Taken together, these results indicate that NPM1 interact with
polZ in the nucleoplasm.
We next examined whether DNA-damage induction affects the
interaction between NPM1 and polZ. Exposure of the MRC5sv
cells to ultraviolet irradiation resulted in a decrease in the amount
of polZ while the total levels of NPM1 were not significantly
altered (Fig. 4e, input blot). Interestingly, following ultraviolet
irradiation the interaction between polZ and NPM1 was
transiently lost, and reappeared at later time points, as detected
by co-IP (Fig. 4e). Similarly, analysis by the PLA showed a
transient loss of interaction between polZ and NPM1 following
ultraviolet irradiation (Fig. 4f, quantified in Fig. 4g). Ultraviolet
irradiation of MRC5sv cells co-expressing GFP-tagged polZ and
mCherry-tagged NPM1 resulted in recruitment of polZ but not of
NPM1 into replication foci (Supplementary Fig. 5b), further
supporting the observation that NPM1 releases polZ following
ultraviolet irradiation. To identify the region of polZ that
interacts with NPM1, a series of FLAG-polZ deletion mutants
















































































































































































Figure 2 | Secondary functional TLS screen. (a,b) The plasmids used for the secondary TLS screen: A Fluc-expressing gapped plasmid carrying a site-specific
DNA lesion on the non-transcribed strand and a gap on the transcribed strand (a) and a control Rluc-expressing gapped plasmid without a lesion (b). (c) An
outline of the secondary TLS screen. In brief, XPA cells were transfected with the siRNA on day 0 and with the reporter plasmids on day 2. Fluc and Rluc signals
were measured on day 3. (d,e) Histograms describing TLS FC effects caused by the siRNAs (median values over four replicas that were preformed on different
days). Dashed red lines denote the distribution borders of negative control samples. Data from the TT 6-4 PP TLS screen is presented in d, and that from the TT
CPD TLS screen in e. (f,g) Luminescence values of the four biological replicas plotted against each other from the TT 6-4 PP screen (f), and the TT CPD screen
(g). (h) Enrichment of TLS, DNA repair and DNA-damage response pathways within the screen hits. The dashed red line corresponds to a hypergeometric test P
value 0.05. See also Supplementary Fig. 2, Supplementary Data 1 and Supplementary Tables 1 and 2.
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NPM1 resulted in co-precipitation of FLAG-polZ mutants
lacking its regulatory carboxy terminus (Fig. 4h lanes 2–7, and
Fig. 4i), it failed to co-precipitate the FLAG-polZ mutants lacking
the catalytic core of the polymerase (Fig. 4h lanes 8-9, and
Fig. 4i). This suggests that NPM1 interacts with the catalytic core
of polZ.
NPM1 protects DNA polg against proteasomal degradation.
To examine whether NPM1 affects polZ stability, we measured by
flow cytometry the level of ectopically expressed GFP-POLH in
MRC5sv cells that stably express this construct. Knocking down
NPM1 in these cells resulted in a threefold decrease in the
expression of the GFP-polZ construct (Fig. 5a, median values).
When cells expressing GFP-RAD18, a gene fusion of the main E3
ligase responsible for monoubiquitination of PCNA were ana-
lysed, no reduction in RAD18 expression was obtained following
knockdown of NPM1 (Supplementary Fig. 6), which is in
agreement with the functional PCNA ubiquitination in these
cells. Next, we tested whether NPM1 regulates the protein level of
endogenous polZ. Knocking down the expression of NPM1 in
XPA cells caused a significant fourfold decrease in the amount of
the NPM1 protein (Fig. 5b, lanes 1 and 2). A similar result was
obtained with the MRC5sv cells (3.4-fold decrease; Fig. 5c, lanes 1
and 2). Under these conditions, the amount of polZ was sig-
nificantly reduced both in the XPA cells (3.8-fold decrease;
Fig. 5b, lanes 1 and 2) and the repair-proficient MRC5sv cells
(2.9-fold decrease, Fig. 5c, lanes 1 and 2), with no significant
change in POLH mRNA level, as measured by qPCR (Fig. 5d). A
similar effect was observed in ultraviolet-irradiated cells (Fig. 5b
lanes 3 and 4, and Fig. 5c lanes 3 and 4, corresponding to XPA
and MRC5sv cells, respectively). Importantly, ectopic expression
of an siRNA-resistant NPM1 construct rescued the reduction in
polZ caused by the silencing of endogenous NPM1 (Fig. 5e).
Thus, a reduction in the amount of NPM1 causes a decrease in
the amount of endogenous polZ at the post-transcriptional level.
A similar reduction was also observed with polk, which is another
TLS DNA polymerase, but not with poli, the closest homologue
of polZ in mammalian cells (Fig. 5f). Inhibiting the proteasome
using MG132 caused an increase in polZ levels in cells pre-treated
with siRNA against NPM1, but not in those treated with control
siRNA (Fig. 5g). This indicates that NPM1 has an important
function in maintaining the stability of polZ, and protecting it
from proteasomal degradation. The E3 ubiquitin ligases PIRH2
and MDM2 were implicated in the proteasomal degradation of
polZ. Nevertheless, knocking down each of these enzymes or
both, in addition to knocking down NPM1, did not rescue the
polZ level (Supplementary Fig. 7a,b), suggesting that the degra-
dation of polZ upon NPM1 deficiency is not mediated solely by
PIRH2 or by MDM2.
NPM1cþ mutations phenocopy the deficiency in DNA polg.
The C terminus of NPM1 is mutated in B30% of all AML
patients, resulting in loss of the nucleolar localization signal and
the generation of a de novo nuclear export signal. This leads to
mislocalization of mutant NPM1 (designated NPM1cþ ), and
partially of wild-type (wt) NPM1 interacting with it, in the
cytoplasm40,43. These mutations strongly correlate with better
response of patients to chemotherapy and better clinical
outcome44,45. Because of the role of NPM1 in stabilizing polZ
in the nucleus, we hypothesized that mislocalization of NPM1 to
the cytoplasm might cause destabilization of polZ, similar to the
effect that we have observed in cells in which NPM1 was knocked
down. To this end, we examined polZ levels in OCI/AML2 and
OCI/AML3 cell lines derived from AML patients, either without
or with the NPM1cþ mutation, respectively. As can be seen in
Fig. 6a, the amount of polZ was much lower in the NPM1cþ
AML cell line compared with the NPM1wt AML cell line, whereas
the POLH mRNA levels were similar (Fig. 6b). Consistently with
the lower polZ amount, TLS across a TT CPD was lower (two-
tailed t-test, P value o0.003), and more mutagenic (w2-test, P
value o0.01) in the NPM1cþ AML cells compared with the
NPM1wt AML cells (Fig. 6c). Proteasome inhibition using
Table 1 | Summary of the novel TLS genes identified by the 2-stage screen.
Gene symbol Ultraviolet-sensitivity screen 6-4 PP TLS screen CPD TLS screen Examined in MEFs Function category
Fold change P value Fold change P value Fold change P value
ALKBH2 2.2 1.0 10 5 1.5 7.9 104 0.9 2.0 10 1 O Replication/repair
DCLRE1A 1.6 2.3 10 3 1.7 1.2 10 2 1.1 4.0 10 1 O
ERCC4 3.2 o1 10 7 2.8 1.3 10 5 1.2 1.8 10 1 O
MCM3 2.2 o1 10 7 1.6 6.0 10 3 1.5 7.0 10 3 O
RUVBL2 2.7 8.0 10 7 1.7 1.1 10 3 1.3 7.5 10 2 O
RPN1 2.4 o1 10 7 1.5 3.4 10 3 1.1 3.2 10 1 Proteasomal degradation
SMURF2 1.6 2.1 104 1.8 8.6 10 6 1.5 2.8 10 3
UBE2E1 1.5 1.1 10 3 3.0 5.3 10 7 2.5 1.2 10 6 O
UBE2G2 0.7 1.3 10 3 1.7 3.4 10 5 1.1 2.1 10 1
NPM1 1.7 3.8 106 1.8 4.4 10 3 1.6 2.9 10 3 O Chaperon
DNAJC6 1.5 2.4 10 3 1.7 3.2 104 1.1 2.5 10 1
TRIP11 1.6 7.5 10 6 2.5 o1 10 7 2.2 o1 10 7 O Structural Golgi
VCPIP1 0.7 1.6 10 3 1.8 3.3 10 5 1.3 2.3 10 2
CYLD 1.6 8.7 10 5 2.3 1.5 104 1.3 8.3 10 2 O Other
OTUB2 2.0 1.0 10 7 1.8 5.6 104 1.4 1.6 10 2
PAPD7 1.4 2.0 10 2 1.5 1.0 10 3 1.1 1.9 10 1 O
SENP2 1.7 1.3 10 6 1.1 2.5 10 1 1.6 2.7 10 3
The table lists the 17 novel TLS genes identified by the two-stage screen, divided into functional categories.
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MG132 rescued the level of polZ in the NPM1cþ AML cell line
(Fig. 6d), indicating that polZ is subjected to excessive
proteasomal degradation, as was the case in cells in which
NPM1 was knocked down. To further support the notion that it is
the mislocalization of NPM1 in the AML cells that causes the
polZ deficiency, we treated the cells with Leptomycin B, an
inhibitor of nuclear export via exportin 1, previously shown to
prevent the exclusion of NPM1 from the nucleus46. As can be
seen in Supplementary Fig. 8, NPM1 was present mainly in the
cytoplasm in NPM1cþ AML cells, but not in the NPM1wt AML
cells, as expected. Upon addition of Leptomycin B, The NPM1cþ
AML cells exhibited nuclear localization of NPM1, similarly to
the NPM1wt cells. Examining the level of polZ under these
conditions revealed that Leptomycin B treatment did not change
the amount of polZ in NPM1wt AML cells, but caused a
significant increase in polZ in the NPM1cþ AML cells (Fig. 6e),
consistent with a role of NPM1 in stabilizing polZ in the nucleus.
Furthermore, ectopic expression of mCherry-NPM1cþ in
HEK293 cells that stably express GFP-polZ caused a significant
twofold decrease in the amount of GFP-polZ as indicated by flow
cytometry analysis (Fig. 6f,g). This effect was not observed when
























































































































































































































Figure 3 | Validation of TLS candidate genes by qPCR-based and colony-based TLS assays. (a) An outline of the qPCR-based TLS assay. In brief,
following TLS in mammalian cells, the plasmids were extracted under alkaline conditions, and subsequently treated with single-stranded-specific
endonuclease. This ensures that only filled-in plasmids remain intact. TLS efficiency was calculated as the ratio between the products of qPCRs targeting
the filled-in gap-lesion plasmid, and the filled-in control gapped plasmid. (b) qPCR-based TLS assays in MEFs. Ten hit genes were examined for involvement
in TLS across the tobacco smoke-induced lesion BP-G and the ultraviolet-induced damage TT 6-4 PP, with Rev3L, encoding the catalytic subunit
of DNA polymerase-z, serving as a positive control. Data are represented as mean±s.e.m. of 4–6 biological replicas. One-sample t-test, P values are
indicated as a colour code above each column. (c) mRNA knockdown efficiencies by the siRNAs used in b. Values were measured by qPCR and normalized
to sample treated with control siRNA (siCont). Mean values±s.e.m. of three replicas are presented. (d) Colony-based TLS assay across BP-G in
mouse cells. Data are represented as mean±s.e.m. of three biological replicas. All the tested genes gave two-tailed t-test, P values o0.02.
(e) Mutagenicity of TLS as observed in the colony-based TLS assays shown in d. Ninety-six colonies were analysed per condition. w2 P values were
calculated relative to control siRNA. ssDNA, single-stranded DNA.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6437
6 NATURE COMMUNICATIONS | 5:5437 | DOI: 10.1038/ncomms6437 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
Taken together, these results establish a role for NPM1 in the
regulation of TLS, and suggest that the prevalent NPM1cþ
mutation results in reduced levels of polZ, thereby leading to
defective TLS.
Discussion
The multiplicity of TLS DNA polymerases and their low fidelity
suggest the existence of a complex regulation to ensure their
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Figure 4 | NPM1 interacts with DNA polg and regulates polg-promoted TLS. (a) NPM1 is required for effective TLS across site-specific TT CPD, or the
cisplatin-induced site-specific lesions cisPt-GG, and cisPt-GTG in MEFs. Results of gapped plasmid-based, colony-forming TLS assays are presented
as the mean±s.e.m. of three biological replicas. Two-tailed t-test, P values o0.02 for all tested lesions. (b) Co-IP of polZ and NPM1 in extracts from
MRC5sv cells. (c) PLA of polZ and NPM1 in MRC5sv cells (upper panel), polZ-deficient XPV cells (middle panel) and XPV cells complemented with ectopic
polZ expression (bottom panel). Blue, DAPI (4,6-diamidino-2-phenylindole) staining of the DNA in the nucleus; green, polZ-NPM1 interaction detected by
the assay. White scale bars correspond to 10mm. (d) Quantification of the interacting foci shown in c, based on at least 140 cells of each type. Mean
values±s.e.m. are presented. (e–g) PolZ-NPM1 interaction is transiently lost following ultraviolet irradiation. (e) Co-IP of polZ and NPM1 extracted
from MRC5sv cells at different time points after ultraviolet irradiation with 10 J m 2. (f) PLA of polZ and NPM1 in unirradiated and ultraviolet irradiated
cells. Blue, DAPI staining of the DNA in the nucleus; Green, polZ–NPM1 interaction. White scale bars correspond to 10mm. (g) Quantification of the
interacting foci shown in f, based on at least 100 cells of each type. Mean values±s.e.m. are presented. (h) NPM1 interacts with the catalytic core of polZ.
NPM1 was precipitated from HEK293FT cells expressing a serious of FLAG-POLH deletion mutants. Co-precipitation of the FLAG-POLH mutants is shown
in the upper panel, whereas the expression of POLH mutants before precipitation is shown in the lower panel. (i) The functional domains of polZ.
PAD, polymerase-associated domain; PIP1 and PIP2, PCNA-interacting protein domains 1 and 2, respectively; UBZ, ubiquitin-binding zinc finger;
NLS, nuclear localization signal. All blots are representative of three independent experiments. IB, immunoblotting; siCont, control siRNA. POLH FL, POLH
full length.
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the regulation that enables a low and tolerable mutation burden is
only partially understood. We reasoned that given its complexity,
TLS in mammalian cells is regulated by additional as yet
unidentified genes, and searched for those using a two-stage
functional siRNA screen. Having two functional assays, one of
which was specific for TLS, and a subsequent stringent validation
protocol that included analysis by additional TLS assays, was
anticipated to reduce the number of false hits. The high selectivity
of the screens for TLS genes is demonstrated by the high
enrichment of known TLS genes within the hits, in contrast to
other DNA repair pathways. The switch to mouse cells for the
subsequent qPCR validation enabled us to gain more validation
power by using different siRNA oligos to target the mouse genes,
and by demonstrating that the hits are not cell type- or human-
specific. It should be noted that the secondary gapped plasmid-
based screen used in this study measures TLS outside the
chromosomal context, and hence TLS genes that are associated
with chromatin structure or replication fork progression are
unlikely to be scored. Such TLS genes might have been detected in
the primary ultraviolet-sensitivity screen. The E3 ligase RAD18
that mediates PCNA monoubiquitination was not scored in our
screen, although we have previously shown that it is required for
effective TLS in the gap-lesion plasmid assay23. This might have
been caused by inefficient knockdown of the gene. Our screening
strategy had led to the identification of 17 new TLS genes, six of
which, namely NPM1, SMURF2, UBE2E1, CYLD, OTUB2 and
VCPIP1, do not have obvious homologues in E. coli or S.
cerevisiae. Of the 17 TLS genes, 10 were further examined by a
transcription-/translation-independent qPCR version of the TLS
assay in mouse cells, and at least four, namely CYLD, NPM1,
PAPD7 and RUVBL2, also affected mutation rates across the BP-
G lesion, further supporting their role in TLS. Most of our hits
were detected when screening for TLS across the TT 6-4 PP
lesion, with only few exceptions detected in the TT CPD screen,
perhaps owing to the robustness of CPD bypass by the highly
specialized polZ. Virtually, all of our hits seem to have a positive
role in TLS, with the exception of USP1, which is a known
negative TLS regulator responsible for de-ubiquitination of
monoubiquitinated PCNA47.
Most of the new TLS hits can be classified into four functional
categories, including DNA replication and repair genes, genes
affecting proteasomal degradation, chaperons and Golgi-related
genes (Table 1). The replication/repair category contains five
genes, including the helicase subunit MCM3, which is involved in
the formation of replication forks; ALKBH2, which is involved in
a direct reversal repair pathway; DCLRE1A, which functions in
the repair of DNA crosslinks; ERCC4, which function in HRR as
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Figure 5 | NPM1 protects DNA polg from proteasomal degradation. (a) MRC5sv cells stably expressing GFP-POLH were treated with siRNA against
NPM1 or non- targeting control siRNA (siCont). GFP-polZ levels were quantified by flow cytometry. (b,c) Immunoblot of polZ extracted from human
XPA cells (b) and MRC5sv cells (c) pretreated with siRNA against NPM1 or non-targeting siCont. When indicated, cells were ultraviolet-irradiated 15 h
before extraction with 2 J m 2 (b) or 10 J m 2 (c). Upper and lower blots were done with the same extracts. (d) PolZ downregulation is not at the
transcription level. qPCR of POLH and NPM1 mRNA levels from cells pretreated with siRNA against NPM1, normalized to non-targeting siRNA-treated cells.
Mean values±s.e.m. of three replicas are presented. (e) Immunoblot of polZ extracted from MRC5sv cells pretreated with siRNA against NPM1 and
complemented by ectopic expression of an siRNA-resistant NPM1 construct. (f) Polk, but not poli, is also affected by NPM1 knockdown. Immunoblots
of polk and poli extracted from MRC5sv cells pretreated with siRNA against NPM1, or non-targeting siCont. (g) Accumulation of polZ following
proteasomal inhibition. MRC5sv cells were treated with non-targeting siRNA or siRNA against NPM1 and then subjected to MG132 for the indicated
time periods in order to inhibit proteasomal activity. Tubulin served as a loading control. All blots are representative of three independent experiments.
Irad., irradiated.
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TLS suggests cross talk between DNA replication, repair and
damage tolerance. Interestingly, the recruitment of DCLRE1A to
sites of damage requires the ubiquitination of PCNA by RAD18
in a similar manner to TLS polymerases48. Since TLS polymerases
are implicated in crosslink repair, it is tempting to speculate that
DCLRE1A participates in coordinating the TLS and crosslink
repair pathways, a task in which FAAP20 was recently
implicated49. RUVBL2 plays an essential part in several
chromatin-remodeling complexes including INO80 that
regulates transcription by sliding nucleosomes on DNA. Of
note, the INO80 complex is also required for removal of histones
at sites of damage and was recently suggested to regulate DNA-
damage tolerance50,51.
The next two categories include four genes involved in protein
degradation by the proteasome and two genes encoding
chaperons, consistent with the importance of regulating the
stability of TLS components. UBE2E1 and UBE2G2 are E2
ubiquitin ligases; SMURF2 is an E3 ubiquitin ligase; and RPN1
forms part of the regulatory subunit of the 26S proteasome.
The chaperons group includes NPM1, which is discussed below,
and DNAJC6, which belongs to the DNAJ/HSP40 family of
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Figure 6 | The NPM1cþ mutation causes DNA polg degradation and TLS deficiency. (a) Immunoblot of polZ extracted from OCI/AML2 and OCI/AML3
cells expressing wt NPM1 and NPM1cþ alleles, respectively. (b) qPCR of POLH and NPM1 mRNA levels from OCI/AML2 and OCI/AML3 cells. Mean
values±s.e.m. of three replicas are presented. (c) TLS in OCI/AML2 and OCI/AML3 cells. TLS across a site-specific TT CPD using the gapped plasmid-based,
colony-forming TLS assay is shown. Mean values±s.e.m. of three replicas are presented, two-tailed t-test, P value o0.003). Mutagenicity was addressed by
sequencing 96 TLS events per cell line, w2-test, P value o0.01. (d) Proteasomal inhibition rescued PolZ deficiency in NPM1cþ AML cells. PolZ levels in OCI/
AML2 and OCI/AML3 cells pretreated with MG132 for the indicated time to inhibit proteasomal activity. Tubulin served as a loading control. (e) NPM1 nuclear
retention rescued PolZ deficiency in NPM1cþ AML cells. PolZ levels in OCI/AML2 and OCI/AML3 cells pretreated with Leptomycin B (LMB) for the indicated
time or its solvent as a control. Tubulin served as a loading control. (f–k) Density plots and histograms representing fluorescence-activated cell sorting analysis
of HEK293 cells stably expressing GFP-polZ, and partially transfected with mCherry-tagged NPMcþ (f,g), wt NPM1 (h,i) and control mCherry (j,k). Data from
mCherry-negative (untransfected) cells in (g,i,k) are in red and correspond to the left y axis, while that from mCherry-positive (transfected) cells are in blue and
correspond to the right y axis. All blots are representative of three independent experiments. siCont, control siRNA.
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Of note, the Caenorhabditis elegans homologue of DNAJC6
(w07a8.3) was previously scored as a hit in a mutagenesis screen,
which further supports its involvement in TLS52. The category of
Golgi-related genes includes TRIP11 and VCPIP1. VCPIP1 is a
deubiquitinating enzyme that mediates the reassembly of Golgi
stacks after mitosis. Importantly, it also interacts with VCP/p97,
which was recently found to regulate TLS21,22,53. There are four
additional TLS hits including two de-ubiquitination enzymes,
namely OTUB2 and CYLD, the latter being a negative regulator of
the NF-kB pathway; SENP2 that participates in SUMO signalling;
and PAPD7 that is an RNA-specific ribonucleotidyl transferase
that plays a role in the turnover of aberrant mRNAs54. The new
TLS genes, which belong to diverse pathways and functions, are
likely to be useful for further analysis of TLS in mammalian cells
and its interaction with other cellular pathways.
The finding that NPM1 is a regulator of TLS adds an
unexpected dimension to the role of this multi-functional protein
in preventing genome instability55–57, and uncovers a new key
player of TLS regulation via proteasomal degradation. By
protecting polZ from degradation, NPM1 enables TLS to fulfil
its function of overcoming replication obstacles, thereby
preventing DSB and genome instability58. It was previously
shown that two E3 ubiquitin ligases promote polyubiquitination
of polZ and target it for proteasomal degradation: MDM2
(ref. 59) and CRL4(CDT2) (ref. 60). In addition, PIRH2 targets
polZ to proteasomal degradation via a ubiquitination-
independent pathway61. Thus, the cellular levels of polZ are
tightly regulated. Human HSP90 was reported to facilitate the
corrected folding of polZ into its active form62, and GEI-17 was
shown to prevent the polyubiquitination and subsequent
degradation of polZ by CRL4(CDT2) following genotoxic stress
in C. elegans60. While GEI-17 is dispensable for polZ stability at
steady state, NPM1 is critical for maintaining a functional pool of
polZ in the absence of external DNA damaging agents. Thus,
even if GEI-17 activity is conserved in mammals, it does not seem
to overlap with the role of NPM1 in protecting polZ stability, but
rather work subsequently. The transient release of polZ from
NPM1 following ultraviolet irradiation might enable polZ to
reach damaged sites in the DNA through its affinity to
monoubiquitinated PCNA and preform TLS, however, this
dynamics of polZ needs further investigation.
It was recently reported that polZ is involved in the resistance to
araC, a drug routinely used to treat AML, which exerts its
therapeutic activity via incorporation into DNA and inhibiting
replication63. Thus, our results may explain, at least in part, the
better prognosis and response to chemotherapy treatment of AML
patients carrying the NPM1cþ mutation, which causes exclusion
of NPM1 from the nucleus, leading to a polZ deficiency, and
therefore more effective killing of the leukaemic cells by drugs such
as araC. PolZ was recently implicated in the cellular response to
doxorubicin treatment64. Although we demonstrated that the
NPM1cþ OCI/AML3 AML cells carry low levels of polZ, they
were reported to be more resistant to doxorubicin than OCI/AML2
cells65. The sensitivity of the AML cells to doxorubicin is most likely
governed by processes other than TLS such as DSB repair and
apoptosis, which might also be regulated by NPM1. Such processes
can mask the effect of polZ, which might be secondary for this
drug. The results presented here underscore the critical role of
NPM1 in maintaining genome stability, and highlight polZ and
NPM1, and in particular their interaction, as potential targets for
development of drugs for AML therapy.
Methods
Plasmids construction. pGL4.13 and pGL4.73 reporter plasmids (Promega) served
as backbones for the reporter gapped plasmids used in the screen. Restriction-free
cloning was performed using PfuUltra II Fusion High-Fidelity DNA Polymerase
(Stratagene). The following cloning steps were performed: (i) Bsa1 and BstX1
restriction sites were mutated; (ii) the SV40 promoter was replaced with a CMV
promoter, taken from pRL-CMV (Promega); (iii) the ColE1 origin of replication
was relocated to the region in between the CMV promoter and the reporter gene;
and (iv) the AMP resistance cassette was replaced with a chloramphenicol resistance
one, and was relocated in the firefly construct to the region in between the
CMV promoter and the reporter gene. The mCherry-tagged NPM1 and NPM1cþ
constructs were produced by fusing the mCherry coding region (Clontech) to the
carboxyl terminus of the human NPM1 or NPM1cþ coding region. FLAG-tagged
polZ truncations were produced by introducing the FLAG epitope in the amino
terminus of the human POLH coding region, and deleting the indicated fragments
by restriction-free cloning. siRNA-resistant human NPM1 construct was design by
introducing silence mutations in the sequence corresponding to the siRNA oligo: 50-
GAGCACCAGUUAUCUUUAA-30.
Cell cultures. SV40-transformed MRC5sv, XPA (XP12RO), XPV (XP30RO) and
XPVPOLHþ human fibroblasts were gifts from A.R. Lehmann (University of Sus-
sex, Brighton, UK). C57BL/6 MEFs were gifts from N. de Wind (Ludwig Max-
imilians University, Munich, Germany). OCI/AML2, OCI/AML3 and HEK293FT
cells are commercially available. GFP-polZ expressing cells were produced by
infection of MRC5sv or HEK293FT cells with GFP-POLH encoding lentiviruses,
followed by fluorescence-activated cell sorting (BD FACSAria) for GFP-expressing
cells. Human fibroblasts were cultured in MEM, AML lines in MEM-a modifica-
tion, and MEFs and HEK293FT in DMEM (Gibco). Each medium was supple-
mented with 2 mM alanyl-glutamine (Biological Industries), 100 units ml 1 of
penicillin, 100mg ml 1 of streptomycin (Biological Industries) and 10–15% fetal
bovine serum (Gibco). Throughout the screening steps, cells were maintained at
37 C in a 5% CO2 and 4% O2 atmosphere.
Ultraviolet-sensitivity screen. Human XPA cells were reverse-transfected in 96-
well plates with 25 nM siGenome SMARTpool siRNA libraries (Dharmacon), using
Hiperfect transfection reagent (Qiagen). Following incubation of 2 days, cells were
washed twice with Hanks’ buffer (Sigma) and irradiated in Hanks’ buffer at a dose
of 1 J m 2 ultraviolet C using a low-pressure mercury lamp (TUV 15W G15T8,
Philips). Following irradiation, the cells were maintained under growth conditions
for 48 h. Cell viability was determined using CellTiter-Glo (Promega). In order to
reduce misinterpretation of toxic effects of certain siRNAs, each sample was nor-
malized using its corresponding non-irradiated sample transfected with the same
siRNA. Ultraviolet sensitivity was calculated with respect to control wells.
TLS screen. Human XPA cells were transfected with the siRNA hits from the
ultraviolet-sensitivity screen at a concentration of 10 nM. The cells were incubated
for 2 days, after which they were co-transfected with a mixture of 2.5 ng Fluc gap-
lesion plasmid and 2.5 ng Rluc control gapped plasmid. Following incubation of
24 h, Fluc and Rluc signals were sequentially measured using the dual-luciferase
reporter assay (Promega). TLS extent values were calculated as the ratio between
Fluc and Rluc signals in respect to samples transfected with control siRNA, and
were corrected for having two different reporters as described in the statistical
analysis section. Exclusion of false-positive hits due to off-target effects of the
siRNA was achieved by de-convolution of selected siRNA pools and testing each of
the four siRNA oligos separately. Gap-lesion plasmids were constructed as
described66.
Statistical analysis of the primary TLS-specific screen. Viability was measured
using luminescence readouts for a set of 1,100 siRNA pools with or without
ultraviolet irradiation in three independent biological replicas. This can be repre-
sented by: IUV,ij; Ino UV,ij where ‘i’ stands for the gene index (siRNA pool) and ‘j’ for
the repeat index. All intensity values are given after log2 transformation. The assay
has a 96-well format such that each plate contains nine negative controls of several
kinds (non-targeting siRNA, RNA-induced silencing complex (RISC)-free siRNA
and siRNA targeting XPA, which is already defective in the cells). Normalization
was done by setting the mean intensity of the negative controls in each plate to be
equal to the mean intensity of the negative control wells over all the plates. This
was done separately for unirradiated plates and ultraviolet-irradiated plates, and
the data were corrected accordingly. For each plate, the corresponding ultraviolet
effect of the negative control wells is given by:
Dcont ¼ ½Ino UV;ij IUV;ij ð1Þ
8j¼ 1, 2, 3, where average is over i A negative control wells. Estimation of the noise
level was done using intensity-dependent noise model67. This estimation assigns a
s.d. value to each siRNA according to the mean intensity value. The approach was
used since it provides better statistical power and is justified by the log Gaussian
nature of the light intensity measurements. The statistic used for the analysis is:
dij ¼ Ino UV;ij  IUV;ij Dcont ð2Þ
This represents the ultraviolet effect associated with a specific siRNA in a
specific repeat with respect to the control ultraviolet effect. According to the null
hypothesis, this statistic is distributed with zero mean and an intensity-dependent
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variance,





A P value was calculated based on this null hypothesis for each siRNA in each
repeat. The three P values calculated for each siRNA were then combined using a
Fisher meta P value to get a single P value per siRNA pool. We call a gene
‘ultraviolet sensitive’ if two conditions are satisfied: 8% FDR, and a median fold
change (FC) of either FC 41.5 or FC o0.8; these values, which are represented by
the red dashed vertical lines on Fig. 1b, were set according to the distribution of the
negative control siRNAs.
Statistical analysis of the secondary TLS-specific screen. The TT 6-4 PP
screen, TT CPD screen and the NL correction assay where measured each in four
independent biological repeats. Thus for each lesion, each siRNA (i) in each replica






NL;j ; j ¼ 1; 2; 3; 4, where ‘F’
stands for Fluc intensity and ‘R’ for Rluc intensity. Each measured value is com-
pared with a similar experiment with the negative control siRNAs discussed above.
A natural statistic then is (the bar represents average over the four replicas):
Ti ¼ Ri  Fi  Rcontrol  Fcontrol
 
 RiNL  FiNL RcontrolNL  FcontrolNL
 h i
ð4Þ
A difficulty arises when analysing this data, namely, the two numbers Fij and R
i
j ,
measured from the same well, are strongly dependent in terms of transfection
efficiency, which is not uniform between repeats and between wells in the same
plate. The way we overcome this problem is by a normalization that keeps the
difference in each well as was measured originally. This was done by setting the
Rluc values to be the same for all replicates and the Fluc values to fit the differences.
Fi;newj ¼ Ri þ dij ; dij ¼ Fij Rij; R
i;new




¼ Var½dij  ð6Þ
and the intensity distribution does not change. All three assays (TT 6-4 PP screen,
TT CPD screen and NL correction) were normalized by this method. When using
the new values, the variance of the statistic Ti defined above becomes:





where the values Var Fi
h i
are taken from intensity-dependent noise estimation, as
was done for the ultraviolet-sensitivity screen. Thus, formulating the null
hypothesis as:
H0 : Ti  N 0; Var½Fi þVar½FiNL
 
ð8Þ
We chose a threshold that combines 10% FDR and a median FC of either FC
41.5 or FC o0.7 (represented by the red dashed vertical lines on Fig. 1f,g), which
was set according to the distribution of the negative control siRNAs.
qPCR-based and colony-based TLS assays. MEFs of wt origin were reverse-
transfected with 10 nM siRNA. Following incubation for 2 days, the cells were co-
transfected with the gap-lesion plasmid and the control gapped plasmid that had been
used in the TLS screen. Cells were maintained for 12 h, after which their plasmid
content was extracted under alkaline conditions, in which only covalently closed
plasmids remained non-denatured. In the qPCR-based TLS assay, remnants of non-
filled gapped plasmids were digested by the single-stranded DNA-specific S1-endo-
nuclease (1.6 unitsml 1, 30 min incubation). Reactions were terminated by adding
33 mM EDTA, followed by heat inactivation and purification by a Wizard SV PCR
clean-up kit (Promega). TLS analysis was performed by qPCRs using a SYBR Green
reagent (KAPA Biosystems). Discrimination between the filled-in gap-lesion plasmid
and the control gapped plasmid was achieved based on two primer sets; one targeted
the Fluc gene and the other the Rluc gene. The ratio between the two qPCR products,
normalized to samples treated with control siRNA, served to assess the extent of TLS.
In the colony-based TLS assay, the extracted plasmids were transformed into a TLS-
defective E. coli recA strain, which was plated in parallel on Luria broth-kanamycin
(for repaired gap-lesion plasmids) and Luria broth-chloramphenicol (for repaired
control plasmids). The ratio of kanamycin/chloramphenicol resistant E. coli colonies
represents the efficiency of TLS in the mammalian cells, and sequence analysis of
plasmids extracted from individual colonies provides DNA sequence alterations
during TLS. The siRNA sequences are listed in Supplementary Table 3.
qPCR for mRNA evaluation. Total RNA was extracted from the cells 48–72 h after
transfection with siRNA, using the Perfect-Pure RNA cultured cells kit (5-PRIME).
cDNA was produced using High capacity cDNA reverse transcription kit (Applied
Biosystems). A quantity of 5 ng cDNA was taken for qPCR analysis using SYBR
Green reagent (KAPA Biosystems). The data was normalized according to mea-
surements of the mouse HPRT and RLP19 genes, or the human GAPDH and HPRT
genes. The primers used for the qPCRs are listed in Supplementary Table 4.
Immunoblot analysis. When indicated, cells were transfected with 15 mM siRNA
(Dharmacon) using Hiperfect transfection reagent (Qiagen). Cells were maintained
under growth conditions for 3 days, after which they were lysed using RIPA buffer
supplemented with protease inhibitor cocktail and phenylmethanesulfonyl fluoride
(PMSF) (Sigma). For PCNA-ubiquitination measurements, Triton-soluble frac-
tions were extracted by incubating the cells for 5 min at 4 C in buffer A (100 mM
NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM PIPES (pH 6.8), 1 mM EGTA and
0.2% Triton X-100). Following removal of the buffer (Triton-soluble fraction), cells
were rinsed once with cold PBS, and the adhering cellular material (Triton-inso-
luble fraction) was collected by scrapping and was extracted by incubating at 37 C
for 45 min in buffer B (same as buffer A but containing 50 mM NaCl and no Triton
X-100) supplemented with 60 units DNaseI (Sigma). Protein concentration was
determined using the BCA protein assay (Thermo Scientific). Protein extracts were
fractionated by SDS–polyacrylamide gel electrophoresis, after which they were
transferred to a polyvinylidene difluoride (PVDF) membrane and probed with
antibodies specific for polZ (B-7, Santa Cruz Biotechnology, diluted 1:500), poli
(60,668, Novus, diluted 1:1,000), polk (ab57070, Abcam, diluted 1:1,000), Npm1
(FC82291, Sigma, diluted 1:20,000), FLAG (M2, Sigma, diluted 1:1,000), APE1
(AB194, Abcam, diluted 1:2,000), and tubulin (DM1A, Sigma, diluted 1:20,000).
Proteins were visualized using SuperSignal West Pico Chemiluminescent substrate
(Pierce). Quantification was done by ImageJ software. Uncropped blots are pre-
sented in Supplementary Fig. 9.
Co-immunoprecipitation. Cells were rinsed twice in cold PBS and lysed in Triton
lysis buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 10% glycerol and
1% Triton X-100) supplemented with protease and phosphatase inhibitors (Sigma)
for 1 h at 4 C. Samples were pre-treated with protein A/G PLUS agarose beads (Santa
Cruz Biotechnology), and then incubated with 2mg rabbit anti polZ (H300, Santa
Cruz Biotechnology), 2mg rabbit IgG (Santa Cruz Biotechnology) or 2mg mouse anti
FLAG (M2, Sigma) for 2 h, followed by adding protein A/G PLUS agarose beads or
Protein A/G MagBeads (Genscripts) for additional 1 h. Beads were washed three times
with lysis buffer, and two additional times with lysis buffer that contained also
250 mM NaCl. Beads were boiled in SDS buffer, and were taken for immunoblot
analysis.
Immunostaining and PLA. The PLA assay was preformed according to the man-
ufacturer’s instructions (OLINK Bioscience). In brief, cells were plated on 12 mm
coverslips pre-coated with 10mg ml 1 fibronectin (Sigma) and fixed with 3% par-
aformaldehyde. When indicated, cells were ultraviolet irradiated with 10 J m 2 at
time points before fixation. Permeabilization was done with 0.1% Triton X-100.
Coverslips were blocked and then probed with rabbit anti polZ (AB17725, Abcam,
diluted 1:500) and mouse anti-NPM1 (FC82291, Sigma, diluted 1:500). Anti-rabbit-
plus and anti-mouse-minus PLA probes were added, ligated and amplified according
to the manufacturer’s instructions. Immunostaining of NPM1 was done using anti-
NPM1 (FC82291, Sigma, 1:500). Images were captured with Zeiss Axio-Observer Z1
microscope and analysed with CellProfiller software68.
Proteasome or nuclear export inhibition. Proteasomal activity was inhibited by
treating MRC5sv or AML cells with 10 mM MG132 (Sigma) for 1–4 h. NPM1cþ
nuclear export was inhibited by treating AML cells with 20 nM Leptomycin B
(Santa Cruz Biotechnology) for 3–7 h.
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